Increased urinary cortisol levels during the menopause transition.

Increased urinary cortisol levels during the menopause transition. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Increased urinary cortisol levels during the menopause transition. Abstract Text:

Nancy F Woods,Molly C Carr,Eunice Y Tao,Heather J Taylor,Ellen S Mitchell,Nancy F Woods,Molly C Carr,Eunice Y Tao,Heather J Taylor,Ellen S Mitchell,

OBJECTIVE: To determine whether cortisol levels change prospectively during the menopausal transition (MT); whether these changes are associated with changes in the hypothalamic-pituitary-ovarian axis (follicle-stimulating hormone [FSH] and estrone glucuronide [E1G]), stressors, or menopause symptoms; and whether women who experienced a rise in cortisol levels during the transition had behavioral practices, stressors, vasomotor symptoms, or mood or sleep disturbances that affected hypothalamic-pituitary-adrenal axis function. DESIGN: One hundred sixty-nine women in the middle or late MT or early postmenopause stages provided monthly urine specimens for cortisol, FSH, and E1G, and rated symptoms and stress levels as part of a longitudinal study of the MT. Of these women, 91 completed a transition to the next MT stage: from early to middle (n = 30), middle to late (n = 39), or late to postmenopause (n = 22) and were eligible for inclusion in the analyses. RESULTS: Cortisol increased from 7 to 12 months before the late MT stage to 7 to 12 months after onset of the late MT stage. There were no differences before and after the middle MT stage or the final menstrual period. Women with increased cortisol (>10 ng/mg creatinine) during the late MT stage had more severe vasomotor symptoms than those without changes, but did not differ in terms of age, body mass index, levels of FSH or E1G, health practices, exercise, mood, sleep, cognition, or stress levels. CONCLUSIONS: Cortisol levels rise with age, but have not been linked to stages of the MT. Increased cortisol levels during the late MT stage, when menstrual irregularities are greatest, suggests increases in adrenal androgens and intraabdominal fat with menopause, and may influence risk of cardiovascular disease, vasomotor symptoms, mood, cognition, and bone loss.

Increased urinary cortisol levels during the menopause transition. Publishing Authors By Initials

NF Woods,MC Carr,EY Tao,HJ Taylor,ES Mitchell,NF Woods,MC Carr,EY Tao,HJ Taylor,ES Mitchell,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Increased urinary cortisol levels during the menopause transition. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Menopause (New York, N.Y.)

VOLUME: 13

Page Numbers: 212-21

Journal Abbreviation:

ISSN: 1072-3714

DAY: 28

MONTH: 04

YEAR: 2006

Increased urinary cortisol levels during the menopause transition. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9433353

Increased urinary cortisol levels during the menopause transition. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Increased urinary cortisol levels during the menopause transition. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Increased urinary cortisol levels during the menopause transition.

AFFILIATION: Department of Family and Child Nursing, University of Washington, Seattle, WA 98195-7260, USA. nfwoods@u.washington.edu

Country: United States

AGENCY: United States NINR

GRANT: P50-NR-02323

ACRONYM: NR

MEDLINETA: Menopause

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Increased urinary cortisol levels during the menopause transition Related Publications

• A Two-Dimensional X-ray Scattering System for In-Situ Time-Resolving Studies of Polymer Structures Subjected to Controlled Deformations.
• Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization.
• Anaesthesia for endovascular treatment of cerebral aneurysms.
• Can folic acid protect against congenital heart defects in Down syndrome?
• Depressed mood symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study.
• Effect of continuous display of cerebral perfusion pressure on outcomes in patients with traumatic brain injury.
• Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
• Endotoxemia in pregnant cows: Comparisons of maternal and fetal effects utilizing the chronically catheterized fetus.
• Function of Candida albicans adhesin Hwp1 in biofilm formation.
• Glutamate acts at NMDA receptors on fresh bovine and on cultured human retinal pigment epithelial cells to trigger release of ATP.
• Glycemic Index, Glycemic Load and diabetes in a sample of older Australians.
• How to build a biofilm: a fungal perspective.
• Images in neuroscience.
• Images in neuroscience. Devic's disease.
• Impact of strain and D-amphetamine on impulsivity (delay discounting) in inbred mice.
• Increased urinary cortisol levels during the menopause transition.
• Metabolic and drug profiling.
• Molecular and cellular basis of congenital heart disease.
• Mycotic intracavernous carotid aneurysm.
• NEW BAT CHIGGERS FROM THAILAND AND THE SOLOMON ISLANDS WITH NOTES ON THE SUBGENUS SASATROMBICULA VERCAMMENGRANDJEAN (ACARINA: TROMBICULIDAE).
• Neuropsychological function and delay discounting in methamphetamine-dependent individuals.
• Nonconscious priming after 17 years: invulnerable implicit memory?
• Oral cobalamin remains medicine's best kept secret.
• Rescue of progeria in trichothiodystrophy by homozygous lethal Xpd alleles.
• Satisfaction with end-of-life care for nursing home residents with advanced dementia.
• Sudden infant death syndrome: risk factors for infants found face down differ from other SIDS cases.
• The effects of major abdominal surgery, enteral and parenteral nutrition on pancreatic function and morphology.
• The validity and reliability of scales for the evaluation of end-of-life care in advanced dementia.
• Trimethylaminuria (fish-odour syndrome) and oral malodour.
• Use of herbal/natural supplements according to racial/ethnic group.